The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.806805
Reference12 articles.
1. Discontinuation of imatinib therapy after achieving a molecular response
2. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
3. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
4. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia
5. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug-induced tumoral disease: A global pharmacovigilance database analysis;Therapies;2023-11
2. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07
3. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors;Clinical Lymphoma Myeloma and Leukemia;2016-10
4. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia;Current Hematologic Malignancy Reports;2016-02-27
5. CML as Part of Dual Malignancies—A Retrospective Analysis: Possible Mechanisms and Review of Literature;Indian Journal of Hematology and Blood Transfusion;2015-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3